Replies to post #31503 on Biotech Values

[DewDiligence]

>IDIX – Excuse my laziness to look this up. I wonder why idix dropped so much over the last 12 months.<

In descending order of importance (IMO):

1. Question surrounding the viability of NM283 on account of the dose reduction due to GI side effects.

2. The early success of VRTX’s VX-950 in treating HCV.

3. General market conditions.

--
I think IDIX is a great long-term buy at the current price. Regards, Dew